Core Insights - The year 2025 marks significant advancements in China's healthcare security system, showcasing resilience and a focus on people's health amidst modernization efforts [1] Group 1: Multi-layered Medical Security System - The "1+3+N" framework emphasizes a multi-layered medical security system, including a unified medical insurance information platform, basic medical insurance, major illness insurance, and support for commercial health insurance [2] - Reimbursement rates for inpatient expenses under employee and resident medical insurance have reached approximately 80% and 70%, respectively, with improvements in outpatient services [2] Group 2: Dual Drug Catalogs - The introduction of the "dual catalog" system for basic medical insurance and commercial health insurance marks a significant step in defining the boundaries of coverage, facilitating access to innovative drugs [3] - In 2025, the basic medical insurance catalog added 114 new drugs, with 50 being innovative drugs, achieving a negotiation success rate of 88% [3] Group 3: Provincial Coordination - The push for provincial coordination in basic medical insurance aims to enhance fairness and sustainability, with 20 provinces already advancing this initiative [5] - The focus is on optimizing fund management and ensuring uniform policy implementation across regions [5] Group 4: Anti-Competition Measures - The "anti-involution" strategy aims to stabilize drug pricing and maintain quality by preventing irrational price competition in the pharmaceutical industry [6][7] - Mechanisms have been introduced to ensure fair pricing and enhance clinical selection in drug procurement [7] Group 5: Real-World Research - Real-world research (RWS) has been established as a key tool for evaluating the comprehensive value of drugs and medical technologies, aiming to support sustainable fund management [8] - The National Medical Insurance Administration is developing a nationwide evaluation system to integrate real-world data into decision-making processes [8] Group 6: Long-term Care Professionals - The introduction of long-term care professionals aims to strengthen the workforce for long-term care services, with over 3,500 candidates participating in certification exams across multiple provinces [10] - The long-term care insurance system has expanded to cover nearly 300 million people, benefiting over 3.3 million individuals with disabilities [10] Group 7: Maternity Insurance System - The maternity insurance system aims for "no out-of-pocket" expenses for childbirth within policy coverage, with 2.55 billion people enrolled in the program [11] - Efforts are underway to include more demographics, such as flexible workers and migrant workers, into the maternity insurance coverage [11] Group 8: Drug Traceability Codes - The implementation of drug traceability codes has led to the collection of 39.885 billion codes, enhancing consumer protection and combating counterfeit drugs [13] - By July 2025, all medical institutions will be required to implement full traceability for drug sales [13] Group 9: Three-Settlement Reform - The "three-settlement" reform aims to streamline payment processes in the healthcare sector, significantly reducing the payment cycle for pharmaceutical companies [14] - The initiative includes immediate, direct, and synchronized settlements to enhance service efficiency for patients [14] Group 10: Medical Service Pricing Guidelines - The establishment of national medical service pricing guidelines aims to standardize pricing across provinces, addressing discrepancies and improving service quality [16] - The National Medical Insurance Administration has issued 36 batches of guidelines, with plans to complete 40 by 2026 [16]

Core Viewpoint - The year 2025 marks significant advancements in China's medical insurance system, showcasing resilience and a focus on people's health through various reforms and initiatives [1][20]. Group 1: "1+3+N" Multi-layered Medical Security System - The National Healthcare Security Administration emphasizes the establishment of a "1+3+N" multi-layered medical security system, which includes a unified national medical insurance information platform, three levels of basic medical insurance, and support for commercial health insurance and other forms of assistance [2][21]. - The reimbursement rates for inpatient expenses under employee and resident medical insurance have reached approximately 80% and 70%, respectively, while the level of serious illness insurance has increased by 10 to 15 percentage points [2][21]. Group 2: Dual Directory System - The introduction of the "dual directory" system, which includes the National Basic Medical Insurance and Commercial Health Insurance Innovation Drug Directories, represents a significant step in defining the boundaries of basic and commercial insurance [3][23]. - In 2025, the basic medical insurance directory added 114 new drugs, with 50 being innovative drugs of significant clinical value, achieving a historic high [3][23]. Group 3: Provincial Coordination - The push for provincial coordination of basic medical insurance aims to enhance fairness and sustainability within the system, with 20 provinces already advancing this initiative [5][24]. - The National Healthcare Security Administration has mandated the optimization of fund management and the establishment of provincial adjustment funds to support this coordination [5][24]. Group 4: Anti-Overcompetition - The eleventh round of centralized drug procurement has shifted towards a focus on quality and sustainability, with the concept of "anti-overcompetition" introduced to prevent irrational price competition [6][24]. - Mechanisms have been implemented to ensure rational pricing and to enhance clinical choice, allowing medical institutions to report quantities based on specific brands [6][26]. Group 5: Real-World Research - Real-world research (RWS) has been established as a key tool for evaluating the comprehensive value of drugs and medical technologies, aiming to support sustainable fund management and high-quality industry development [7][25]. - The National Healthcare Security Administration is planning to integrate real-world evaluation results into the entire chain of medical insurance payment and management [7][27]. Group 6: Long-term Care Workers - Long-term care workers have been introduced as a new profession to support long-term care services, with over 3,500 candidates participating in skill assessments across 28 provinces [10][29]. - The long-term care insurance system has covered nearly 300 million people, benefiting over 3.3 million individuals with disabilities [10][30]. Group 7: Maternity Insurance System - The maternity insurance system aims to achieve "no out-of-pocket" expenses for childbirth within policy coverage, with 2.55 billion people enrolled in maternity insurance during the 14th Five-Year Plan [11][30]. - The plan includes expanding coverage to flexible workers and improving prenatal care expense coverage [11][12]. Group 8: Drug Traceability Codes - The implementation of drug traceability codes has led to the collection of 39.885 billion codes, enhancing consumer protection and combating drug return issues [14][32]. - By July 2025, all medical institutions will be required to implement full traceability code collection [14][32]. Group 9: Three Settlement Reforms - The "three settlements" reform (instant, direct, and synchronized settlements) aims to reshape the payment ecosystem in the healthcare sector, with significant progress made in instant settlements covering 593,600 medical institutions [15][33]. - Direct settlements are designed to expedite payments to enterprises, reducing the average payment cycle from 180 days to under 30 days [15][33]. Group 10: Medical Service Pricing Guidelines - The National Healthcare Security Administration is working on standardizing medical service pricing across provinces to enhance transparency and service quality [18][35]. - By 2026, the administration aims to complete the compilation of 40 pricing guidelines to unify medical service pricing projects nationwide [18][35].

Core Viewpoint - The article discusses the achievements and future plans of China's medical insurance system during the "14th Five-Year Plan" period, highlighting improvements in coverage, fund management, and the introduction of long-term care insurance [1][3]. Group 1: Medical Insurance Coverage - The national basic medical insurance coverage rate remains stable at around 95%, with a cumulative expenditure of 12.13 trillion yuan, averaging an annual growth rate of 9.1% [1][3]. - By 2024, the number of people covered by basic medical insurance is expected to reach 1.327 billion, with long-term care insurance coverage at 190 million [1][3]. - The direct settlement rate for cross-provincial medical expenses exceeds 90%, and the national medical insurance drug list has been unified, totaling 3,159 types of drugs [1][3]. Group 2: Long-Term Care Insurance - The long-term care insurance system is expected to be implemented nationwide soon, as the current pilot programs have shown positive results [4][7]. - As of June 2025, 253 million people are participating in maternity insurance, with cumulative expenditures of 438.3 billion yuan, benefiting 96.14 million people [6]. - The long-term care insurance aims to alleviate the financial burden of daily care for elderly individuals who have lost their ability to care for themselves, addressing the increasing demand for elderly care services [6][7]. Group 3: Fund Management and Regulation - The medical insurance fund is under increasing pressure, and the focus will be on ensuring fund safety and risk assessment during the "15th Five-Year Plan" period [4][8]. - The reform of payment methods has transitioned from a "post-payment" to a "pre-payment" system, promoting efficiency in medical institutions and reducing patient out-of-pocket expenses by approximately 5% year-on-year [9][10]. - The National Medical Insurance Administration has intensified efforts to combat fraud and misuse of medical insurance funds, recovering 16.13 billion yuan in the first half of the year through inspections of 335,000 medical institutions [10][11]. Group 4: Drug Price Governance - The article emphasizes the importance of drug price governance, with the government supporting market-driven pricing while also maintaining oversight to prevent price manipulation [12][13]. - Since 2018, the government has conducted 10 rounds of centralized drug procurement, covering 435 types of drugs, which has helped lower drug prices and improve accessibility [13][14]. - The National Medical Insurance Administration is committed to ensuring fair pricing practices and encourages public reporting of unusually high drug prices [14].